REGN · Healthcare

REGENERON PHARMACEUTICALS, INC.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-09

Product / Drug Pipeline ProgressImportance 41 · Surprise 42
Third-party reports describe securities litigation alleging that Regeneron’s Phase III aflibercept study used flawed preliminary statistical assumptions and lacked meaningful differentiation from standard therapies. A…
Securities Fraud LitigationImportance 34 · Surprise 42
Regeneron faces securities class-action allegations concerning disclosures about failed or underperforming Phase III studies. Bronstein, Gewirtz & Grossman alleges that, between August 1, 2023, and May 15, 2024,…
Capital Return ProgramImportance 13 · Surprise 6
Regeneron declared a quarterly dividend of $0.94 per share. The dividend was reported alongside the company’s quarterly earnings, which exceeded analyst estimates. The digest did not provide an ex-dividend date, record…

Revenue Performance and MixImportance 24 · Surprise 14
Regeneron reported Q2 2026 revenue of $4.29 billion, exceeding analyst expectations. Diluted EPS was $14.29 for the quarter. Revenue increased year over year, while net income and diluted EPS declined sequentially or…
Capital Return ProgramImportance 10 · Surprise 6
Regeneron confirmed its quarterly dividend following the release of Q2 and first-half 2026 results. The company also provided an update on share repurchases, although the digest did not specify the repurchase amount or…

Revenue Performance and MixImportance 24 · Surprise 14
Regeneron reported Q2 2026 revenue of $4.29 billion, exceeding analyst expectations. Diluted EPS was $14.29 for the quarter. Revenue increased year over year, while net income and diluted EPS declined sequentially or…

Competition and Market ShareImportance 34 · Surprise 42
Regeneron faces new biosimilar competition for Eylea, one of its key ophthalmology products. The competitive pressure is relevant to both standard-dose Eylea and the company’s broader ophthalmology franchise, which…
Securities Fraud LitigationImportance 34 · Surprise 42
Multiple law firms reported that securities class actions have been filed against Regeneron and certain senior executives under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. The allegations…
Revenue Performance and MixImportance 24 · Surprise 14
Regeneron reported Q2 2026 revenue of $4.29 billion, exceeding analyst expectations. Diluted EPS was $14.29 for the quarter. Revenue increased year over year, while net income and diluted EPS declined sequentially or…

Securities Fraud LitigationImportance 34 · Surprise 42
Multiple law firms reported that securities class actions have been filed against Regeneron and certain senior executives under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. The allegations…